CN105770597A - 一种用于治疗胃溃疡的药物制剂 - Google Patents
一种用于治疗胃溃疡的药物制剂 Download PDFInfo
- Publication number
- CN105770597A CN105770597A CN201610227545.5A CN201610227545A CN105770597A CN 105770597 A CN105770597 A CN 105770597A CN 201610227545 A CN201610227545 A CN 201610227545A CN 105770597 A CN105770597 A CN 105770597A
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- semen
- pharmaceutical preparation
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 38
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 61
- 241000660877 Coridius Species 0.000 claims abstract description 24
- 210000000582 semen Anatomy 0.000 claims description 90
- 239000007788 liquid Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 26
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 26
- 241000756943 Codonopsis Species 0.000 claims description 22
- 235000006487 Euryale ferox Nutrition 0.000 claims description 22
- 241000237524 Mytilus Species 0.000 claims description 22
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 241000600871 Euryale <brittle star> Species 0.000 claims 6
- 239000012467 final product Substances 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 abstract description 20
- 231100000397 ulcer Toxicity 0.000 abstract description 20
- 244000268590 Euryale ferox Species 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 14
- 239000002994 raw material Substances 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 10
- 210000000952 spleen Anatomy 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 3
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 235000010894 Artemisia argyi Nutrition 0.000 abstract 1
- 240000004307 Citrus medica Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000110637 Cuscuta chinensis Species 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 240000000982 Malva neglecta Species 0.000 abstract 1
- 235000000060 Malva neglecta Nutrition 0.000 abstract 1
- 240000000233 Melia azedarach Species 0.000 abstract 1
- 241000237536 Mytilus edulis Species 0.000 abstract 1
- 240000004064 Poterium sanguisorba Species 0.000 abstract 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 abstract 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 1
- 241001339782 Scapharca broughtonii Species 0.000 abstract 1
- 241001533115 Thesium chinense Species 0.000 abstract 1
- 244000030166 artemisia Species 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000013372 meat Nutrition 0.000 abstract 1
- 235000020638 mussel Nutrition 0.000 abstract 1
- 229940126532 prescription medicine Drugs 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 description 26
- 241000700159 Rattus Species 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 10
- 229960000381 omeprazole Drugs 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 208000000718 duodenal ulcer Diseases 0.000 description 8
- 206010000087 Abdominal pain upper Diseases 0.000 description 7
- 208000008469 Peptic Ulcer Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000011906 peptic ulcer disease Diseases 0.000 description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 208000010643 digestive system disease Diseases 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002575 gastroscopy Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000030135 gastric motility Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000010728 Meckel diverticulum Diseases 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- XLBIBBZXLMYSFF-UHFFFAOYSA-M Propantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 XLBIBBZXLMYSFF-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 206010066969 Vitello-intestinal duct remnant Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000006766 bile reflux Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000002954 meckel diverticulum Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 229940099209 probanthine Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FPKFWYUHWUOPGP-RJXKWAGSSA-M sodium;(2s)-2,5-diamino-5-oxopentanoic acid;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].OC(=O)[C@@H](N)CCC(N)=O.CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 FPKFWYUHWUOPGP-RJXKWAGSSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗胃溃疡的药物制剂及其用途,组方中含有重量份为:党参、枳实、肉桂、山药、九香虫、薏苡仁、云芝、瓦楞子、淡菜、川芎、地榆、菟丝子、芡实、艾叶、冬葵叶、酸枣仁、甘草、百蕊草、川楝子。本发明的处方,药材选择地道,适合治疗各种溃疡,尤其适合治疗胃溃疡。本发明中成药的组方合理,诸药配合具有理气健脾,温中祛寒,行气止痛之功,各类药材的原料易得,并且遵循中医的处方用药原则,临床实验发现,本发明药物制剂的总有效率达较高,临床用药过程中并未出现不良反应,具有良好的经济和社会价值。
Description
技术领域
本发明属于医药治疗领域,涉及一种治疗胃肠疾病的药物,尤其涉及一种治疗胃溃疡的药物制剂及其用途。
背景技术
近年来,饮食结构的变化加之工作环境的改变,使得消化系统疾病不断攀升,胃溃疡作为消化疾病系统的代表,具有每年增加的趋势,溃疡病或消化性溃疡是一种常见的消化道疾病,可发生于食管、胃或十二指肠,也可发生于胃-空肠吻合口附近或含有胃黏膜的Meckel憩室内,因为胃溃疡和十二指肠溃疡最常见,故一般所谓的消化性溃疡是指胃溃疡和十二指肠溃疡。它之所以称之为消化性溃疡,是因为既往认为胃溃疡和十二指肠溃疡是由于胃酸和胃蛋白酶对黏膜自身消化所形成的,事实上胃酸和胃蛋白酶只是溃疡形成的主要原因之一,还有其他原因可以形成消化性溃疡。由于胃溃疡和十二指肠溃疡的病因和临床症状有许多相似之处,有时难以区分是胃溃疡还是十二指肠溃疡,因此往往诊断为消化性溃疡,或胃、十二指肠溃疡。如果能明确溃疡在胃或十二指肠,那就可直接诊断为胃溃疡或十二指肠溃疡。。
国内外治疗胃溃疡的药品有很多,比如保护胃黏膜药常用的药物有胶体次枸橼酸铋(CBS)、硫糖铝、麦滋林-S、氢氧化铝凝胶、胃膜素等;调整胃肠运动功能药物上腹饱胀用多潘立酮等。打嗝、腹胀或有反流现象为主者,可用胃动力药;抗生素如果胃镜检查发现幽门螺杆菌阳性,应服用抗生素,克拉霉素、羟氨苄青霉素等,都有清除Hp的作用,一般可选用两种,常与胃黏膜保护剂和抑酸剂联合应用;制酸剂常用的药物有碳酸氢钠、氢氧化镁、氢氧化铝凝胶等;止痛药上腹疼痛较重者可口服阿托品、普鲁本辛、颠茄片或654-2,以减少胃酸分泌和缓解腹痛症状;其他对症治疗药可用助消化药,如胰酶、酵母片、乳酶生、二甲硅油片等。如有反酸现象也可用抑酸药如西咪替丁、雷尼替丁、法莫替丁等。防止胆汁反流可服铝碳酸镁、消胆胺以吸附胆汁;有呕血便血者,甲氰米胍口服。
专利中中药治疗胃溃疡的药物不断出现,但是中药制剂效果难以保证,西药治疗也是常用的手段,但是临床常规治疗胃溃疡的疗程较长,见效快速,但是药物副作用大,而且病症经常反复发作,严重影响了人们的生活健康。
发明内容
针对现有技术的缺陷,本发明是针对目前治疗胃溃疡之现状,提供一种治疗效果好的药物制剂,且无毒副作用。
具体而言,本发明是这样实现的。
发明人根据中药配伍经验提供了一种治疗胃溃疡的中药处方,包括以下中药:党参、枳实、肉桂、山药、九香虫、薏苡仁、云芝、瓦楞子、淡菜、川芎、地榆、菟丝子、芡实、艾叶、冬葵叶、酸枣仁、甘草、百蕊草、川楝子。
处方的各原料用量在本发明的重量份范围都具有较好的疗效,所述的配方以及重量份为:党参11-17份、枳实3-8份、黑豆皮5-10份、肉桂8-17份、山药15-25份、九香虫1-3份、薏苡仁5-10份、云芝4-11份、瓦楞子3-7份、淡菜8-14份、川芎6-16份、地榆3-9份、菟丝子5-12份、芡实2-8份、艾叶1-3份、冬葵叶6-11份、酸枣仁10-25份、甘草6-12份、百蕊草3-9份、川楝子4-10份。
为达到了最优的效果,对所述的配方以及重量份为:党参14份、枳实6份、肉桂13份、山药20份、九香虫2份、薏苡仁8份、云芝7份、黑豆皮8份、瓦楞子5份、淡菜11份、川芎13份、地榆6份、菟丝子8.5份、芡实5份、艾叶2份、冬葵叶9份、酸枣仁17份、甘草9份、百蕊草6份、川楝子7份。或者:
党参15份、枳实7份、肉桂12份、山药19份、黑豆皮7份、九香虫1份、薏苡仁8.5份、云芝8份、瓦楞子6份、淡菜11份、川芎13份、地榆6份、菟丝子8.5份、芡实6份、艾叶2份、冬葵叶9份、酸枣仁17份、甘草8份、百蕊草7份、川楝子8份。
本发明的治疗胃溃疡的药物制剂中所使用的各味中药材的功用如下:
黑豆皮:味甘,性凉。
归经:归脾、肺、肾经。
功能主治:养血平肝、祛风解毒,主治头痛,阴虚烦热,盗汗,风痹,湿毒,痈疮,眩晕等。百蕊草:味辛,性平。
功能主治:清热解毒,解署。用于肠炎,肺脓疡,扁桃体炎,中署,急性乳腺炎,淋巴结结核,急性膀胱炎。
艾叶:味辛,性温。
归经:归肝、脾、肾经。
功能主治:散寒止痛,温经止血。用于少腹冷痛,经寒不调,宫冷不孕,吐血,衄血,崩漏经多,妊娠下血;外治皮肤瘙痒。醋艾炭温经止血。用于虚寒性出血。
川楝子:味苦,性寒。
归经:归肝、小肠、膀胱经。
功能主治:舒肝行气止痛,驱虫。用于胸胁、脘腹胀痛,疝痛,虫积腹痛。
菟丝子:味甘,性温。
归经:归肝、肾、脾经。
功能主治:滋补肝肾,固精缩尿,安胎,明目,止泻,用于阳痿遗精,尿有余沥,遗尿尿频,腰膝酸软,目昏耳鸣,肾虚胎漏,胎动不安,脾肾虚泻。
芡实:味甘、涩,平。
归经:归脾、肾经。
功能主治:益肾固精,补脾止泻,祛湿止带。用于梦遗滑精,遗尿尿频,脾虚久泻,白浊,带下
冬葵叶:味甘,性寒。
功能主治:清热.行水,滑肠。治肺热咳嗽,热毒下痢,黄疸,二便不通,丹毒,金疮。
酸枣仁:味甘,无毒。
功能主治:能安和五脏,大补心脾。故血不归脾,而睡卧不宁者,多用之。
甘草:味甘,性平。
归经:入脾、胃、心、肺经。
功能主治:补中益气,清热解毒,祛痰止咳,缓急止痛。
淡菜:味甘,性温。
功能主治:补虚,去胸中烦热,降丹石毒。
川芎:味辛,性温。
归经:归肝、胆、心包经。
功能主治:活血行气,祛风止痛。用于月经不调,经闭痛经,症瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。
党参:味甘,性平。
归经:归脾、肺经。
功能主治:补中益气,健脾益肺。用于脾肺虚弱,气短心悸,食少便溏,虚喘咳嗽,内热消渴
枳实:味苦,性温。
归经:归脾、胃经。
功能主治:破气消积,化痰散痞。用于积滞内停,痞满胀痛,泻痢后重,大便不通,痰滞气阻胸痹,结胸;胃下垂,脱肛,子宫脱垂。
肉桂:味辛,性热。
归经:入肾、脾,膀胱经。
功能主治:补元阳,暖脾胃,除积冷,通血脉。治命门火衰,肢冷脉微,亡阳虚脱,腹痛泄泻,寒疝奔豚,腰膝冷痛,经闭症瘕,阴疽,流注,及虚阳浮越,上热下寒。
山药:味甘,性平。
归经:归脾、肺、肾经。
功能主治:补脾养胃,生津益肺,用于脾虚食少,久泻不止,虚热消渴,炒山药补脾健胃,泄泻便溏。
薏苡仁:味甘,性凉。
归经:归脾、胃、肺经。
功能主治:健脾渗湿,除痹止泻,清热排浓。用于水肿,脚气,小便不利,湿痹拘挛,脾虚泄泻,肺痈,肠痈;扁平疣。
云芝:味甘,性寒。
归经:肝;脾;肺经。
功能主治:健脾利湿;止咳平喘;清热解毒;抗肿瘤。主慢性活动性肝炎;肝硬变;慢性支气管炎;小儿痉挛性支气管炎;咽喉肿痛;多种肿瘤;类风湿性关节炎;白血病。
瓦楞子:味咸,性平。归肺、胃、肝经。
功能主治:消痰化瘀,软坚散结,制酸止痛。用于顽痰胶结,黏稠难咯,瘿痼,瘰疬,癍瘕痞块,胃痛泛酸。
九香虫:味甘,性温。归胃、肾经。
功能主治:温中,下气,止呃。用于虚寒呃逆,呕吐。
本发明所述的药物制剂适合治疗各种消化道溃疡,尤其适合治疗胃溃疡。
本发明所述的药物制剂为胶囊剂、片剂、水煎剂、颗粒剂中的一种。
本发明对以上的处方经过认真的研究,根据中医用药的合理性,发明提出了具体的一种治疗胃溃疡的水煎剂的制备方法,具体步骤为:
(1)党参、枳实、肉桂、山药、九香虫、薏苡仁、云芝、瓦楞子、淡菜、川芎、地榆、菟丝子、芡实、艾叶、冬葵叶、酸枣仁、甘草、百蕊草、川楝子去杂洗净得到原料混合物;
(2)将步骤(1)的原料混合物加6-10倍体积的纯净水浸泡1.5小时,快火煎开后,再慢煎30分钟,倒出煎液,再加入2-5倍体积的纯净水,慢煎20分钟,再倒出煎液两次倒出的煎液混合搅匀即可。
水煎剂的服用方法为一天一副,将煎液分成一天两次服用,早晚各一次,饭前1小时服用。
本发明对以上的处方经过认真的研究,根据中医用药的合理性,发明提出了具体的一种治疗胃溃疡的颗粒剂的制备方法,具体步骤为:
(1)将云芝、淡菜、芡实、山药、艾叶、冬葵叶、酸枣仁和百蕊草加2000ml水浸泡1小时,快火煎开后,再慢煎30分钟,倒出煎液500ml,再加入300ml的纯净水,慢煎20分钟,再倒出煎液200ml,再加入500ml的水,继续慢煎30分钟,将煎液倒出,与前两次倒出的煎液混合搅匀即可;
(2)将步骤2)煎液减压浓缩得相对密度为1.05的浓缩膏;
(3)党参、枳实、肉桂、川芎和地榆研磨成粗粉,加80%乙醇提取2次,每次1小时,合并药液,静置24小时,备用;
(4)将九香虫、薏苡仁、瓦楞子、菟丝子、甘草、川楝子粉碎成细粉过80目筛后用适量70%乙醇提取2次,每次1.5小时,收集提取液,静置24小时,备用;
(5)取第(3)、(4)步骤中制得的上清液,减压回收乙醇,浓缩至70℃,密度为1.05的浸膏,干燥后与步骤(4)的浸膏混合,备用。
(6)测定步骤(5)中的浸膏重量,加入其重量10%的甘露醇和糊精的混合物,其中甘露醇和糊精的混合物中乳糖和糊精的重量比为1:1;加入适量的15%的淀粉浆,过16目筛制粒,干燥,分装即得颗粒剂。
与现有技术相比,本发明治疗胃溃疡的颗粒剂具有以下优点:
(1)本发明的处方,药材选择地道,适合治疗各种溃疡,尤其适合治疗胃溃疡。本发明中成药的组方合理,诸药配合具有理气健脾,温中祛寒,行气止痛之功,各类药材的原料易得,并且遵循中医的处方用药原则,临床实验发现,本发明药物制剂的总有效率达到100%,临床用药过程中并未出现不良反应,具有良好的经济和社会价值。
(2)本发明提供的制备方法简单,适合大生产。
具体实施例
以下所述,仅为本发明的具体实施方式,本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到的变化或替换,都应涵盖在本发明的保护范围之内。
实施例1:水煎剂的制备方法,含有以下重量份原料药:
党参11克、枳实3克、黑豆皮5克、肉桂8克、山药15克、九香虫1克、薏苡仁5克、云芝4克、瓦楞子3克、淡菜8克、川芎6克、地榆3克、菟丝子5克、芡实2克、艾叶1克、冬葵叶6克、酸枣仁10克、甘草6克、百蕊草3克、川楝子4克。
具体的制备方法为:
(1)党参、枳实、肉桂、山药、九香虫、薏苡仁、云芝、瓦楞子、淡菜、川芎、地榆、菟丝子、芡实、艾叶、冬葵叶、酸枣仁、甘草、百蕊草、川楝子去杂洗净得到原料混合物;
(2)将步骤(1)的原料混合物加6-10倍体积的纯净水浸泡1.5小时,快火煎开后,再慢煎30分钟,倒出煎液,再加入2-5倍体积的纯净水,慢煎20分钟,再倒出煎液两次倒出的煎液混合搅匀即可。
水煎剂的服用方法为一天一副,将煎液分成一天两次服用,早晚各一次,饭前1小时服用。
实施例2:水煎剂的制备方法,含有以下重量份原料药:
党参17克、枳实8克、黑豆皮10克、肉桂17克、山药25克、九香虫3克、薏苡仁10克、云芝11克、瓦楞子7克、淡菜14克、川芎16克、地榆9克、菟丝子12克、芡实8克、艾叶3克、冬葵叶11克、酸枣仁25克、甘草12克、百蕊草9克、川楝子10克。
制备方法同实施例1。
实施例3:水煎剂的制备方法,含有以下重量份原料药:
党参14克、枳实6克、肉桂13克、山药20克、九香虫2克、薏苡仁8克、云芝7克、黑豆皮8克、瓦楞子5克、淡菜11克、川芎13克、地榆6克、菟丝子8.5克、芡实5克、艾叶2克、冬葵叶9克、酸枣仁17克、甘草9克、百蕊草6克、川楝子7克。
制备方法同实施例1。
实施例4:水煎剂的制备方法,含有以下重量份原料药:
党参15克、枳实7克、肉桂12克、山药19克、黑豆皮7克、九香虫1克、薏苡仁8.5克、云芝8克、瓦楞子6克、淡菜11克、川芎13克、地榆6克、菟丝子8.5克、芡实6克、艾叶2克、冬葵叶9克、酸枣仁17克、甘草8克、百蕊草7克、川楝子8克。
制备方法同实施例1。
实施例5:颗粒剂的制备方法,含有以下重量份原料药:
党参11克、枳实3克、黑豆皮5克、肉桂8克、山药15克、九香虫1克、薏苡仁5克、云芝4克、瓦楞子3克、淡菜8克、川芎6克、地榆3克、菟丝子5克、芡实2克、艾叶1克、冬葵叶6克、酸枣仁10克、甘草6克、百蕊草3克、川楝子4克。
具体步骤为:
(1)将云芝、淡菜、芡实、山药、艾叶、冬葵叶、酸枣仁和百蕊草加2000ml水浸泡1小时,快火煎开后,再慢煎30分钟,倒出煎液500ml,再加入300ml的纯净水,慢煎20分钟,再倒出煎液200ml,再加入500ml的水,继续慢煎30分钟,将煎液倒出,与前两次倒出的煎液混合搅匀即可;
(2)将步骤2)煎液减压浓缩得相对密度为1.05的浓缩膏;
(3)党参、枳实、肉桂、川芎和地榆研磨成粗粉,加80%乙醇提取2次,每次1小时,合并药液,静置24小时,备用;
(4)将九香虫、薏苡仁、瓦楞子、菟丝子、甘草、川楝子粉碎成细粉过80目筛后用适量70%乙醇提取2次,每次1.5小时,收集提取液,静置24小时,备用;
(5)取第(3)、(4)步骤中制得的上清液,减压回收乙醇,浓缩至70℃,密度为1.05的浸膏,干燥后与步骤(4)的浸膏混合,备用。
(6)测定步骤(5)中的浸膏重量,加入其重量10%的甘露醇和糊精的混合物,其中甘露醇和糊精的混合物中乳糖和糊精的重量比为1:1;加入适量的15%的淀粉浆,过16目筛制粒,干燥,分装即得颗粒剂。
实施例6:颗粒剂的制备方法,含有以下重量份原料药:
党参17克、枳实8克、黑豆皮10克、肉桂17克、山药25克、九香虫3克、薏苡仁10克、云芝11克、瓦楞子7克、淡菜14克、川芎16克、地榆9克、菟丝子12克、芡实8克、艾叶3克、冬葵叶11克、酸枣仁25克、甘草12克、百蕊草9克、川楝子10克。
制备方法同实施例5。
实施例7:颗粒剂的制备方法,含有以下重量份原料药:
党参14克、枳实6克、肉桂13克、山药20克、九香虫2克、薏苡仁8克、云芝7克、黑豆皮8克、瓦楞子5克、淡菜11克、川芎13克、地榆6克、菟丝子8.5克、芡实5克、艾叶2克、冬葵叶9克、酸枣仁17克、甘草9克、百蕊草6克、川楝子7克。
制备方法同实施例5。
实施例8:颗粒剂的制备方法,含有以下重量份原料药:
党参15克、枳实7克、肉桂12克、山药19克、黑豆皮7克、九香虫1克、薏苡仁8.5克、云芝8克、瓦楞子6克、淡菜11克、川芎13克、地榆6克、菟丝子8.5克、芡实6克、艾叶2克、冬葵叶9克、酸枣仁17克、甘草8克、百蕊草7克、川楝子8克。
制备方法同实施例5。
实施例9:动物模型试验
香砂养胃丸主要治疗胃中胃于不用阳温和足、湿阻气滞所致的胃痛、痞满,症见胃痛隐隐、脘闷不舒、呕吐酸水、嘈杂不适、不思饮食、四肢倦怠,是一种治疗胃溃疡具有显著疗效的药物,本发明用来做中药阳性对照试验组(C组)。
奥美拉唑肠溶片,适应症为适用于胃溃疡、十二指肠溃疡、应激性溃疡、反流性食管炎和卓-艾综合征,治疗效果较好,本发明选择其作为西药阳性对照组(D组)。
9.1、动物模型建模以及分组
昆明大鼠70只,体重180-220g之间,大鼠术前禁食12h,正常组10只、假手术组10只、模型组10只、奥美拉唑组10只,香砂养胃丸10只,实施例3水煎液组(A组)10只,实施例7颗粒剂组(B组)10只,自由饮用口服补液盐(OregonRevisedStatutes,ORS),ORS配方是氯化钠3.5克、碳酸氢钠2.5克、氯化钾1.5克、葡萄糖粉20克加纯水至1000ml。
大鼠术前禁食、自由饮口服补液盐12-16h,10%水合氯醛(3.5mL/kg体质量)肌肉注射麻醉。用0.5%碘伏消毒大鼠腹部皮肤,沿左肋下缘开腹,将胃轻轻拉出。
用镊子夹住距幽门部3mm胃体部区域。将事先吸好0.18mL矿物油和0.02mL60%乙酸的注射器的针头插入挟闭区的胃腔内,在挟闭区的胃腔内注入0.18mL矿物油和0.02mL60%乙酸,45s后从胃部吸出乙酸,再向胃腔内注入2mL生理盐水,1min后吸出,以终止反应。将胃复位,向切口内滴入青霉素钠注射液0.1mL(以4mL生理盐水加入80万单位青霉素钠,混匀),逐层关腹。假手术对照组以灭菌纯水代替乙酸。术后大鼠禁食、自由饮用口服补液盐。术中操作轻揉并注意无菌操作,以减少粘连。
9.2、给药方式以及操作
术后大鼠禁食24h,自由饮用口服补液盐。12h后正常进食水,饮用水为纯水,每日投放的鼠粮要定量管理。奥美拉唑(阿斯利康)按人剂量的6.25倍计算大鼠有效剂量,即1.04mg/kg体重灌胃,每日一次;本发明实施例3的水煎剂5ml/次,本发明实施例7的颗粒剂4g/kg,每日一次,给药时间均为9:00。大鼠禁食、自由饮水24h后10%水合氯醛腹腔麻醉(3mL/kg体质量)。开腹,腹主动脉采血,不抗凝,低温静置2h后3000r/min离心10min,收集血清备用ELISA法检测。取出胃,沿胃大弯剪开,生理盐水将胃黏膜冲洗干净,取出胃部溃疡处,-70℃冰箱保存,以备ELISA法检测。
9.3、血清PGE2含量检测
加样品稀释液作为空白对照,将标准品依次加入孔中,其余各孔加样品血清50μL,在标准品孔和样品孔中加入100μL的酶标记液,36℃温育反应60min。洗液清洗5次后每孔加入底物A、B液各50μL,36℃避光温育反应15min。每孔加入50μL终止液,终止反应。TECAN多功能酶标仪(InfiniteM200,奥地利)测定450nmOD值。根据标准曲线回归方程计算样品的浓度。
9.4、胃组织匀浆PGE2含量检测
大鼠胃组织称重后剪碎,按10mL/g加生理盐水匀浆,得到胃组织匀浆液。加样品稀释液作为空白对照,将标准品各50μL依次加入孔中,其余各孔加样品50μL。样品孔中加入10μL生物素标记液,在标准品孔和样品孔中加入100μL的酶标记液。36℃温育反应60min。洗液清洗5次后每孔加入底物A、B液各50μL。36℃避光温育反应15min。每孔加入50μL终止液,终止反应。测定450nmOD值。根据标准曲线回归方程计算样品的浓度。
9.5、胃组织匀浆EGF含量检测
大鼠胃组织称重后剪碎,按10mL/g加生理盐水匀浆,得到胃组织匀浆液。1孔只加样品稀释液作为空白对照,将标准品各50μL依次加入孔中,其余各孔加样品50μL。实验过程同“9.2”项。
9.6、统计学方法
采用SPSS13.0软件,组间比较用单因素方差分析,结果均以表示,以P<0.05为差异有统计学意义。
9.7、结果
表1PGE2、PGE2、EGF含量如下表
注:
与正常对照组比较,##P<0.01;
与模型对照组比较,P<0.05,P<0.01;
与奥美拉唑组比较,¥P<0.05,¥¥P<0.01;
与香砂养胃丸组相比,%P<0.05,%%P<0.01。
从表1可以看出,通过PGE2、PGE2、EGF含量,模型组明显低于正常对照组(P<0.01),表明造模成功,且假手术组与正常对照组之间没有显著性差异,排除手术影响;通过比较PGE2、PGE2、EGF含量,奥美拉唑组、香砂养胃丸组及本发明颗粒剂、水煎剂的与模型对照组具有统计学差异,适合进一步推广应用。
9.8炎症因子的检测
使用美国R&D公司生产的ELASA检测试剂盒、TECAN公司的多功能酶标仪(InfiniteM200,奥地利),按说明书进行血清IL-6、IL-8的水平的检测。
表2胃溃疡模型大鼠第4d血清中IL-6、IL-8动态变化
组别 | IL-6(pg/ml) | IL-8(pg/ml) |
正常组 | - | - |
假手术组 | - | - |
模型组 | 757.23±23.38 | 685.44±33.36 |
A组 | 701.36±33.02¥% | 455.53±41.29¥¥%% |
B组 | 689.56±33.60¥%% | 440.02±51.23¥¥%% |
C组 | 720.22±41.23 | 500.91±45.23 |
D组 | 711.63±37.31 | 496.39±39.69 |
注:
与正常对照组比较,##P<0.01;
与模型对照组比较,P<0.05,P<0.01;
与奥美拉唑组比较,¥P<0.05,¥¥P<0.01;
与香砂养胃丸组相比,%P<0.05,%%P<0.01。
从表2可以看出,在第4d,假手术组与正常对照组大鼠血清中IL-6、IL-8之间没有显著性差异,排除手术影响;奥美拉唑组、香砂养胃丸组及本发明颗粒剂、水煎剂的与模型对照组具有统计学差异,并且本发明颗粒剂组IL-6、IL-8均明显低于奥美拉唑组、香砂养胃丸组,二者均具有统计学差异。适合进一步推广应用。
实施例10:动物模型试验和体外实验
将实施例1、2、4制备的水煎液和实施5、6、8制备的颗粒剂替代实施例9中使用的实施例3的颗粒剂,重复实施例9,结果发现实施例1、2、4、5、6、8制备的制剂具有较好的疗效。
实施例11、本发明胃肠助影剂在治疗胃溃疡中的临床情况:
11.1、病例选择:
我院从2013-2015年选择胃溃疡患者300例进行临床观察,病人随机分成三组,治疗组300例,分别为治疗组①组和②组,每组100人,对照组100例,各组患者病历、年龄、性别、健康等因素基本一致,无显著差异,具有可比性。
11.2、治疗方法:
治疗组①组:口服本发明实施例3制备的水煎剂,水煎剂的服用方法为一天一副,将煎液分成一天两次服用,早晚各一次,饭前1小时服用,7天为一疗程,连续服用3个疗程;
治疗组②组:口服本发明实施例7制备的颗粒剂,每次20g,每日3次,7天为一疗程,连续服用3个疗程;超声检查前一小时口服本发明实施例7制备的散剂。
对照组患者:按治疗剂量服用奥美拉唑+枸橼酸莫沙比利颗粒+阿莫西林克拉维酸钾,7天为一疗程,连续服用3个疗程。
11.3、诊断标准:
(1)慢性病程,周期性发作,常与季节变化、精神因素、饮食不当有关;或长期服用能致溃疡的药物如阿司匹林等。
(2)上腹隐痛、灼痛或钝痛,服用碱性药物后缓解。典型胃溃疡常于剑突下偏左,好发于餐后半小时到1~2小时。疼痛常伴反酸嗳气。
(3)基础泌酸量及最大泌酸量测定有助诊断。胃溃疡的基础泌酸量正常或稍低,但不应为游离酸缺乏。
(4)溃疡活动期大便隐血阳性。
(5)x线钡餐检查可见龛影及粘膜皱襞集中等直接征象。单纯局部压痛,激惹变形等间接征象仅作参考。
(6)胃镜检查,可于胃部见圆或椭圆、底部平整、边缘整齐的溃疡。根据溃疡面所见,可分为:①活动期:溃疡面为灰白或褐色苔膜覆盖,边缘肿胀,色泽红润、光滑而柔软。②愈合期:苔膜变薄,溃疡缩小,其周围可见粘膜上皮再生的红晕;或溃疡面几乎消失,其上有极少的薄苔。③瘢痕期:溃疡面白苔已消失,变成红色充血的瘢痕;可见皱襞集中。
具备以上(1)(2)(5)或(2)(6)项者可作胃溃疡诊断,对诊断为胃溃疡者须与恶性溃疡鉴别,凡能进行胃镜检查者应做胃粘膜活检予以确诊。
11.5、治疗结果:
治愈:溃疡及炎症均消失,胃部隐痛、钝痛、胀痛、烧灼样痛等胃部疼痛消失,胃动力恢复,新陈代谢恢复正常。
显效:溃疡消失或溃疡面积缩小50%以上,其周围组织炎性反应减轻或消退,胃部不适减轻,胃动力有所恢复。
无效:溃疡面积无变化或缩小不到50%或症状无变化。
表3治疗组和对照组的治疗效果如下
组别 | 治愈 | 显效 | 无效 | 有效率(%) |
治疗②组 | 83 | 17 | 0 | 100 |
治疗①组 | 78 | 20 | 2 | 98 |
对照组 | 33 | 51 | 16 | 84 |
从表3可以看出,经过治疗其中治疗②组:治愈83例,显效17例,无效0例,有效率为100%;治疗①组:治愈78例,显效20例,无效2例,总有效率为98%;对照组治愈33例,显效51例,无效16例,总有效率为84%。以上结果显示,治疗组的治愈率和总有效率明显高于对照组。
表4治疗组和对照组的随访个体治疗效果如下
组别 | 随访个体 | 复发个体 | 复发率 |
治疗②组 | 60 | 1 | 1.67% |
治疗①组 | 74 | 1 | 0 |
对照组 | 30 | 8 | 26.67% |
通过表4可以看到:对溃疡愈合患者在疗程结束后6个月时进行内镜随访,统计溃疡复发率。其中治疗①组74例获得随访,治疗②组60例获得随访,对照组治愈者30人获得随访,两组胃溃疡复发率比较见表2。以上实验结果表明,本发明中药组合物在用于胃溃疡的治疗时,具有治愈率高,不易复发的优点,各项统计数据皆由于西药治疗对照组。
11.6、典型案例
病例1:马某,男38岁,2014年来我院检查,患者自诉做过胃镜,患者长期厌食,腹胀等现象,大约两年的时间,最近病情严重,主诉最近时常胃痛,服用过奥美拉唑肠溶胶囊、枸橼酸莫沙比利颗粒,效果不佳,经朋友介绍来我院检查,服用本发明实施例7的颗粒剂,7天之后,患者自诉胃很舒服,疼痛腹胀感基本消失,后继续服用本发明药物14天,痊愈,6个月电话随访没有复发。
病例2:李某,女40岁,当地市医院诊断为慢性胃溃疡,来我院检查时口服硫酸钡造影剂检查,患者胃呈鱼钩型,空腹无胃潴流;胃窦粘膜皱襞排列不规则,增粗。胃壁蠕动性较差,十二指肠球部形态正常,服用各种治疗胃溃疡的药比如香砂养胃丸等中药和西药,效果不佳,后经人介绍来我院治疗,服用本发明实施例3的水煎剂,7天之后,患者自诉胃很舒服,疼痛腹胀感基本消失,食欲增加,后继续服用本发明药物14天,痊愈,6个月电话随访没有复发。
实施例12:毒性验证
12.1、急性毒性试验
受试中药制剂:本发明实施例5-8所制造的药物制剂,按1:2加纯化水,制成溶液,备用。
试验动物:普通级昆明小鼠,体重20g±5g,雌雄各半,雌性小鼠均无孕。
小鼠灌胃本发明中药药物制剂配制的溶液,当灌胃剂量达到735.5g生药/kg剂量时,给药后小鼠出现轻微活动减少,1小时左右恢复正常,给药后连续观察7天,无一动物死亡,其全身状况、饮食、摄水、小便和体重增长均正常。
试验结果表明:小鼠灌胃实施例5-8所制造的药物制剂的最大给药量为735.5g生药/kg/d(LD50>735.5g生药/kg)。本发明的中药粉每日临床用药总量最大为0.15g生药/kg/d;按体重计,小鼠灌胃水煎剂的耐受量为临床病人的4903.3倍。提示该药急性毒性极低,临床用药安全。
12.2、动物长期毒性试验
受试中药制剂:本发明实施例5-8所得中药药物制剂,按1:2加纯化水,制成溶液,备用。试验动物:普通级SD大鼠,体重210g±14g,雌雄各半,雌性大鼠均无孕。
12.3、方法与结果:
4种中药水煎剂:均分为高、中、低三个剂量组,单位体重给药量分别为患者服用量的180、60、20倍;将实验鼠随机分成13组,其中12组分别灌胃3种三个剂量的药物制剂溶液,剩余1组灌胃生理盐水(患者服用量的40倍);所有13组均连续灌胃180天,观察动物全身毒性反应及严重程度,处死后按操作规程检查各部位,并进行血液学,ALT、BUN及心、肝、脾、肺、肾、胃等主要脏器的病理学检查;经过长期喂食,13组大鼠均未出现毒性反应。发育良好。肉眼外观及主要脏器未见异常。外周血象及血清ALT、BUN与对照组比较无病理性改变。病理报告心、肝、脾、肺、肾、胃等均未有意义的改变,因此,认为经病理证实,3种中药水煎剂对动物无慢性毒性表现。
通过以上两个毒性实验,证明本发明按实施例5-8制作的药物制剂是安全的,无毒副作用,可以被患者服用。
Claims (9)
1.一种治疗胃溃疡的药物制剂,其特征在于:所述的药物制剂包括以下中药材:党参、枳实、肉桂、山药、九香虫、薏苡仁、云芝、瓦楞子、淡菜、川芎、地榆、菟丝子、芡实、艾叶、冬葵叶、酸枣仁、甘草、百蕊草、川楝子。
2.根据权利要求1所述的药物制剂,其特征在于,所述的药物制剂包括以下重量份中药材:党参11-17份、枳实3-8份、黑豆皮5-10份、肉桂8-17份、山药15-25份、九香虫1-3份、薏苡仁5-10份、云芝4-11份、瓦楞子3-7份、淡菜8-14份、川芎6-16份、地榆3-9份、菟丝子5-12份、芡实2-8份、艾叶1-3份、冬葵叶6-11份、酸枣仁10-25份、甘草6-12份、百蕊草3-9份、川楝子4-10份。
3.根据权利要求1所述的药物制剂,其特征在于,所述的药物制剂包括以下重量份中药材:党参14份、枳实6份、肉桂13份、山药20份、九香虫2份、薏苡仁8份、云芝7份、黑豆皮8份、瓦楞子5份、淡菜11份、川芎13份、地榆6份、菟丝子8.5份、芡实5份、艾叶2份、冬葵叶9份、酸枣仁17份、甘草9份、百蕊草6份、川楝子7份。
4.根据权利要求1所述的药物制剂,其特征在于,所述的药物制剂包括以下重量份中药材:党参15份、枳实7份、肉桂12份、山药19份、黑豆皮7份、九香虫1份、薏苡仁8.5份、云芝8份、瓦楞子6份、淡菜11份、川芎13份、地榆6份、菟丝子8.5份、芡实6份、艾叶2份、冬葵叶9份、酸枣仁17份、甘草8份、百蕊草7份、川楝子8份。
5.据权利要求1所述的药物制剂,其特征在于,所述的药物制剂为胶囊剂、片剂、水煎剂、颗粒剂中的一种。
6.一种制备权利要求1所述的药物制剂,其特征在于,所述的颗粒剂具体的步骤为:
(1)将云芝、淡菜、芡实、山药、艾叶、冬葵叶、酸枣仁和百蕊草加2000ml水浸泡1小时,快火煎开后,再慢煎30分钟,倒出煎液500ml,再加入300ml的纯净水,慢煎20分钟,再倒出煎液200ml,再加入500ml的水,继续慢煎30分钟,将煎液倒出,与前两次倒出的煎液混合搅匀即可;
(2)将步骤2)煎液减压浓缩得相对密度为1.05的浓缩膏;
(3)党参、枳实、肉桂、川芎和地榆研磨成粗粉,加80%乙醇提取2次,每次1小时,合并药液,静置24小时,备用;
(4)将九香虫、薏苡仁、瓦楞子、菟丝子、甘草、川楝子粉碎成细粉过80目筛后用适量70%乙醇提取2次,每次1.5小时,收集提取液,静置24小时,备用;
(5)取第(3)、(4)步骤中制得的上清液,减压回收乙醇,浓缩至70℃,密度为1.05的浸膏,干燥后与步骤(4)的浸膏混合,备用;
(6)测定步骤(5)中的浸膏重量,加入其重量10%的甘露醇和糊精的混合物,其中甘露醇和糊精的混合物中乳糖和糊精的重量比为1:1;加入适量的15%的淀粉浆,过16目筛制粒,干燥,分装即得。
7.根据权利要求6所述的药物制剂,其特征在于,步骤(6)所述的颗粒剂每包重20g。
8.一种制备权利要求1所述的药物制剂,其特征在于,所述的水煎剂具体的步骤为:
(1)党参、枳实、肉桂、山药、九香虫、薏苡仁、云芝、瓦楞子、淡菜、川芎、地榆、菟丝子、芡实、艾叶、冬葵叶、酸枣仁、甘草、百蕊草、川楝子去杂洗净得到原料混合物;
(2)将步骤(1)的原料混合物加6-10倍体积的纯净水浸泡1.5小时,快火煎开后,再慢煎30分钟,倒出煎液,再加入2-5倍体积的纯净水,慢煎20分钟,再倒出煎液两次倒出的煎液混合搅匀即可。
9.根据权利要求1所述的药物制剂,其特征在于:所述的药物制剂在制备胃溃疡药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610227545.5A CN105770597A (zh) | 2016-04-13 | 2016-04-13 | 一种用于治疗胃溃疡的药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610227545.5A CN105770597A (zh) | 2016-04-13 | 2016-04-13 | 一种用于治疗胃溃疡的药物制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105770597A true CN105770597A (zh) | 2016-07-20 |
Family
ID=56396439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610227545.5A Withdrawn CN105770597A (zh) | 2016-04-13 | 2016-04-13 | 一种用于治疗胃溃疡的药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105770597A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108185088A (zh) * | 2018-03-27 | 2018-06-22 | 广西中医药大学 | 一种荔枝核抗肝损伤保健茶及其制备方法 |
CN109106882A (zh) * | 2018-09-25 | 2019-01-01 | 广州中医药大学(广州中医药研究院) | 一种治疗幽门螺旋杆菌引起的慢性胃炎的中药组合物、制剂及其制备方法 |
CN112493214A (zh) * | 2020-05-21 | 2021-03-16 | 李建新 | 利用注射器制作的麻醉鱼钩 |
-
2016
- 2016-04-13 CN CN201610227545.5A patent/CN105770597A/zh not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
罗若军等: "溃疡生肌汤治疗消化性溃疡90例疗效观察", 《贵阳中医学院学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108185088A (zh) * | 2018-03-27 | 2018-06-22 | 广西中医药大学 | 一种荔枝核抗肝损伤保健茶及其制备方法 |
CN109106882A (zh) * | 2018-09-25 | 2019-01-01 | 广州中医药大学(广州中医药研究院) | 一种治疗幽门螺旋杆菌引起的慢性胃炎的中药组合物、制剂及其制备方法 |
CN112493214A (zh) * | 2020-05-21 | 2021-03-16 | 李建新 | 利用注射器制作的麻醉鱼钩 |
CN112493214B (zh) * | 2020-05-21 | 2022-05-17 | 威海沃尔威体育休闲用品有限公司 | 利用注射器制作的麻醉鱼钩 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102068707B (zh) | 一种b超使用的中药助影剂及其制备方法 | |
CN104225441A (zh) | 一种治疗胃病的中药组合物及其颗粒剂和胶囊剂的制备方法 | |
CN102205107A (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN103751739A (zh) | 治疗慢性胃炎的中药组合物、其在制备治疗慢性胃炎的药物中的应用及其制备方法 | |
WO2022143466A1 (zh) | 一种预防癌症药食同源植物中药组合物 | |
CN105770597A (zh) | 一种用于治疗胃溃疡的药物制剂 | |
CN104288745A (zh) | 一种治疗慢性胃炎的中药 | |
CN103989955A (zh) | 一种治疗胃、十二指肠溃疡、浅表性多发性胃溃疡、糜烂性胃溃疡的药物组合物 | |
CN103341092A (zh) | 一种治疗萎缩性阴道炎的散剂制备方法 | |
CN109106882A (zh) | 一种治疗幽门螺旋杆菌引起的慢性胃炎的中药组合物、制剂及其制备方法 | |
CN104398733A (zh) | 一种治疗肝郁气滞型甲状腺癌的中药制剂 | |
CN105381441A (zh) | 一种用于防治妊娠水肿的中药胶囊剂及制备方法 | |
CN105168628A (zh) | 一种治疗蜂窝组织炎的药物及其制备方法 | |
CN104491364B (zh) | 一种治疗慢性淋巴细胞性甲状腺炎的药丸及制备方法 | |
CN105709005A (zh) | 一种乳康丸 | |
CN106038887A (zh) | 一种治疗胃病中焦寒湿兼有上焦火证的中药 | |
CN106362074A (zh) | 一种治疗纳呆的新型中药组合物及其制备方法 | |
CN105943955A (zh) | 一种用于治疗胃溃疡的中药制剂及制备方法 | |
CN105168944A (zh) | 一种治疗乳腺癌的中药组合物及其用途 | |
CN116077603A (zh) | 一种治疗慢性萎缩性胃炎的中药组合物及其制备方法 | |
CN105797049A (zh) | 一种用于治疗脾虚胃溃疡的药物制剂及其用途 | |
CN104606426A (zh) | 一种治疗慢性胃炎的中药组合物制剂及其制备方法 | |
CN111166850A (zh) | 一种治疗萎缩性胃炎的药物及其制备方法 | |
CN104027789A (zh) | 一种治疗新生儿寒温阻滞型黄疸的中药组合物及其制备方法 | |
CN114949031A (zh) | 一种用于改善脾胃功能、增强免疫力的中药组合物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160720 |
|
WW01 | Invention patent application withdrawn after publication |